AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Expected to Announce Earnings of -$0.77 Per Share

Equities research analysts expect that AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will announce ($0.77) earnings per share (EPS) for the current quarter, according to Zacks. Five analysts have made estimates for AMAG Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.82) and the highest estimate coming in at ($0.69). AMAG Pharmaceuticals posted earnings per share of ($0.75) during the same quarter last year, which would indicate a negative year-over-year growth rate of 2.7%. The business is scheduled to issue its next earnings results on Thursday, August 1st.

On average, analysts expect that AMAG Pharmaceuticals will report full year earnings of ($5.72) per share for the current year, with EPS estimates ranging from ($5.86) to ($5.46). For the next financial year, analysts expect that the firm will post earnings of ($4.29) per share, with EPS estimates ranging from ($4.68) to ($3.67). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for AMAG Pharmaceuticals.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported ($3.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($2.77). AMAG Pharmaceuticals had a negative return on equity of 26.33% and a negative net margin of 30.90%. The firm had revenue of $75.80 million for the quarter, compared to analyst estimates of $90.13 million. During the same period in the previous year, the firm posted ($1.59) earnings per share. The company’s revenue for the quarter was down 35.4% on a year-over-year basis.

A number of research analysts have recently commented on the stock. Zacks Investment Research cut shares of AMAG Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, May 20th. BidaskClub raised shares of AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 15th. ValuEngine raised shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, May 8th. SunTrust Banks set a $13.00 target price on shares of AMAG Pharmaceuticals and gave the stock a “hold” rating in a research report on Tuesday, May 14th. Finally, Cantor Fitzgerald reissued a “hold” rating and set a $14.00 target price (down from $17.00) on shares of AMAG Pharmaceuticals in a research report on Thursday, March 14th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company’s stock. AMAG Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $18.78.

In related news, insider Elizabeth Scott Bolgiano purchased 5,000 shares of the business’s stock in a transaction that occurred on Thursday, May 9th. The shares were purchased at an average cost of $10.93 per share, with a total value of $54,650.00. Following the completion of the acquisition, the insider now directly owns 74,847 shares of the company’s stock, valued at approximately $818,077.71. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO William K. Heiden purchased 10,000 shares of the business’s stock in a transaction that occurred on Thursday, May 9th. The stock was bought at an average cost of $10.70 per share, for a total transaction of $107,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 490,056 shares of the company’s stock, valued at $5,243,599.20. The disclosure for this purchase can be found here. Insiders purchased 25,000 shares of company stock worth $260,750 over the last ninety days. 4.90% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Birchview Capital LP purchased a new stake in AMAG Pharmaceuticals in the fourth quarter valued at approximately $152,000. Monashee Investment Management LLC purchased a new stake in AMAG Pharmaceuticals in the fourth quarter valued at approximately $2,506,000. Great West Life Assurance Co. Can grew its holdings in AMAG Pharmaceuticals by 12.3% in the fourth quarter. Great West Life Assurance Co. Can now owns 44,924 shares of the specialty pharmaceutical company’s stock valued at $629,000 after purchasing an additional 4,919 shares during the period. Two Sigma Investments LP grew its holdings in AMAG Pharmaceuticals by 129.3% in the fourth quarter. Two Sigma Investments LP now owns 250,589 shares of the specialty pharmaceutical company’s stock valued at $3,806,000 after purchasing an additional 141,286 shares during the period. Finally, Rhumbline Advisers grew its stake in AMAG Pharmaceuticals by 18.9% during the fourth quarter. Rhumbline Advisers now owns 102,741 shares of the specialty pharmaceutical company’s stock worth $1,561,000 after buying an additional 16,305 shares during the period.

NASDAQ AMAG opened at $9.25 on Monday. AMAG Pharmaceuticals has a 52 week low of $9.15 and a 52 week high of $26.10. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.13 and a current ratio of 2.30. The firm has a market cap of $321.46 million, a PE ratio of -2.38 and a beta of 0.48.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Read More: How to invest in a bear market

Get a free copy of the Zacks research report on AMAG Pharmaceuticals (AMAG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.